stockrowPerrigo Company plc
PRGO Healthcare Drug Manufacturers Specialty & Generic
Perrigo Company plc’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, down 2.75% from fiscal 2024.
- Revenue
- −5.24%
- EPS
- −494.6%
- Free cash flow
- +138.5%
- Total debt
- −9.62%
Quarter to September 2026, against a year earlier
Follow PRGO
Alert me
Perrigo Company plc (PRGO) Return on invested capital
Perrigo Company plc's return on invested capital over the twelve months to 30 September 2026 was −19.0%, down 7.4 percentage points from fiscal 2025 (−11.6%). Over the past ten years it has ranged from −11.6% (fiscal 2025) to 4.23% (fiscal 2017) — the current reading is the lowest in ten years. That is below the Drug Manufacturers Specialty & Generic industry median of 0.00% and below the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | −11.6% | (12.56) |
| FY2024 | 0.96% | (0.21) |
| FY2023 | 1.17% | 0.58 |
| FY2022 | 0.59% | (3.18) |
| FY2021 | 3.77% | 1.84 |
| FY2020 | 1.93% | 0.69 |
| FY2019 | 1.24% | (0.53) |
| FY2018 | 1.77% | (2.46) |
| FY2017 | 4.23% | 15.46 |
| FY2016 | −11.2% | (11.50) |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| ANIP ANI Pharmaceuticals, Inc. compare | 46.4% |
| XERS Xeris Biopharma Holdings, Inc. compare | 27.2% |
| PBH Prestige Consumer Healthcare Inc. compare | 9.59% |
| TRLV Trulieve Cannabis Corp. compare | 0.00% |
| HCM HUTCHMED (China) Limited Sponsored ADR compare | 0.00% |
| RGC Regencell Bioscience Holdings Limited compare | 0.00% |
| ALVO Alvotech compare | 0.00% |
| BCRX BioCryst Pharmaceuticals, Inc. compare | 0.00% |
| PRGO Perrigo Company plc | −19.0% |
| Drug Manufacturers Specialty & Generic industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)
More on PRGO
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement